![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBczRDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--9aeaa29667fc28a1fc04766e4528f1f75d791721/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/grey-wolf-therapeutics-logo-300x79.png)
Grey Wolf Therapeutics
Grey Wolf is developing next gen immunotherapies that illuminate non-responsive tumors for destruction by the immune system.
Website
www.greywolftherapeutics.comPartner
Brent AhrensInvestment
Series A
Grey Wolf is developing next gen immunotherapies that illuminate non-responsive tumors for destruction by the immune system.
Series A